Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Common Equity (2019 - 2025)

Maxcyte (MXCT) has disclosed Common Equity for 6 consecutive years, with $180.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 15.48% to $180.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $180.3 million, a 15.48% decrease, with the full-year FY2024 number at $206.3 million, down 11.16% from a year prior.
  • Common Equity was $180.3 million for Q3 2025 at Maxcyte, down from $190.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $264.1 million in Q3 2021 to a low of $78.8 million in Q2 2021.
  • A 5-year average of $216.2 million and a median of $232.2 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 691.26% in 2021, then fell 15.48% in 2025.
  • Maxcyte's Common Equity stood at $262.9 million in 2021, then decreased by 3.4% to $254.0 million in 2022, then decreased by 8.58% to $232.2 million in 2023, then dropped by 11.16% to $206.3 million in 2024, then decreased by 12.59% to $180.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Common Equity are $180.3 million (Q3 2025), $190.7 million (Q2 2025), and $199.4 million (Q1 2025).